8-K - LNAI - Equibles

UNITEDSTATESSECURITIES AND EXCHANGE COMMISSION****Washington, DC 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 27, 2022

ENOCHIAN

BIOSCIENCES INC. ****(Exact name of registrant as specified in its charter)

Delaware	000-54478	45-2559340
(State<br> or other jurisdiction	(Commission<br> File Number)	(I.R.S.<br> Employer
of<br> incorporation)		Identification<br> No.)

1927Paseo Rancho Castilla

LosAngeles, CA 90032(Address of principal executive offices)

+1(305) 918-1980

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications<br> pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant<br> to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications<br> pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications<br> pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
Common<br> Stock, par value $0.0001 per share	ENOB	The<br> Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

Nasdaq Notification

On December 16, 2022, Enochian BioSciences Inc. (the “Company”) submitted to The Nasdaq Stock Market LLC (“Nasdaq”) a plan to regain compliance with the Nasdaq Listing Rule 5250(c)(1) (the “Rule”). On December 27, 2022, Nasdaq notified the Company that it had determined to grant an exception to enable the Company to regain compliance with the Rule. Pursuant to such exception, the Company must file with the Securities and Exchange Commission, on or before April 11, 2023, its Annual Report on Form 10-K for the fiscal year ended June 30, 2022, the Quarterly Report on Form 10-Q for the period ended September 30, 2022 and all other filings as required by the Rule.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ENOCHIAN BIOSCIENCES, INC.
By:	/s/ Luisa Puche
	Name: Luisa Puche<br><br>Title: Chief Financial Officer

Date: December 30, 2022